CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• CytomX will report Q1 2026 results before the market opens on May 7: analysts expect (‑$0.14) EPS and $4.682M revenue, after the company missed prior-quarter estimates (reported ‑$0.22 EPS and $0.66M revenue) and faces ~‑$1 EPS forecasts for the current and next fiscal year.
• Insider selling and heavy institutional ownership: CEO and an SVP sold shares in mid‑March (insiders sold 191,063 shares worth ~$1.23M in the last 90 days), while institutions own about 67.8% of the stock.
• Mixed analyst views but overall bullish price targets: multiple brokers have upgraded CTMX and raised targets (Barclays to $16, JPMorgan to $12), producing a consensus "Moderate Buy" and an average price target of $13.44 despite a lone sell rating from Weiss Ratings.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $4.6820 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The firm had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. On average, analysts expect CytomX Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX opened at $4.18 on Friday. CytomX Therapeutics has a 52 week low of $0.76 and a 52 week high of $8.21. The company has a market capitalization of $711.39 million, a PE ratio of -104.50 and a beta of 2.18. The company has a 50 day moving average price of $4.74 and a two-hundred day moving average price of $4.50.

Insider Activity at CytomX Therapeutics

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 118,969 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the completion of the transaction, the chief executive officer owned 1,078,922 shares in the company, valued at approximately $6,926,679.24. This represents a 9.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Marcia Belvin sold 31,492 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $202,178.64. Following the completion of the sale, the senior vice president directly owned 300,760 shares in the company, valued at $1,930,879.20. This represents a 9.48% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 191,063 shares of company stock valued at $1,226,624. Insiders own 6.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in CytomX Therapeutics in the 1st quarter valued at approximately $39,000. Woodline Partners LP bought a new position in shares of CytomX Therapeutics during the 1st quarter worth approximately $1,054,000. Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 103.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company's stock worth $3,963,000 after acquiring an additional 887,218 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of CytomX Therapeutics in the second quarter valued at approximately $32,000. Finally, Marshall Wace LLP raised its holdings in shares of CytomX Therapeutics by 2,650.9% in the second quarter. Marshall Wace LLP now owns 2,353,122 shares of the biotechnology company's stock valued at $5,342,000 after purchasing an additional 2,267,583 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CTMX. Barclays boosted their price target on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the company an "overweight" rating in a report on Thursday, March 19th. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $7.00 to $12.00 in a report on Monday, March 16th. Piper Sandler boosted their target price on CytomX Therapeutics from $10.00 to $12.00 and gave the company an "overweight" rating in a research note on Monday, March 23rd. Cantor Fitzgerald raised their price target on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 4th. Finally, Weiss Ratings cut CytomX Therapeutics from a "hold (c-)" rating to a "sell (d)" rating in a report on Thursday, March 19th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $13.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.